Showing 51-60 of 2206 results for "".
Physicians with Substance Use Disorder, Part I: Overview and A Personal Journey Through Recovery
https://practicalneurology.com/columns/practice-management/physicians-with-substance-use-disorder-part-1-overview-and-a-personal-journey-through-recovery/30090/Chris Bundy, MD, Executive Medical Director, Washington Physicians Health Program, provides an overview of physician substance use disorder, including prevalence, risk factors, and impediments to recovery as well as details about his own journey with recovery.NMOSD Part 3 - Overview of treatment, including goals, triggers, and considerations for switching therapies
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/nmosd-part-3-overview-of-treatment-including-goals-triggers-and-considerations-for-switching-therapies/30089/In this series, Derrick Robertson, MD, Director of the Multiple Sclerosis Division at the University of Southern Florida discusses multiple aspects of NMOSD. Dr. Robertson is talking with us today on behalf of Horizon Therapeutics which is compensating him for his services and is sponsoring this podPD GENEration and Barriers to Parkinson Diagnosis - Part 1
https://practicalneurology.com/diseases-diagnoses/movement-disorders/pd-generation-and-barriers-to-parkinson-diagnosis-part-1/30095/Chantale Branson, MD, Associate Professor of Neurology at Morehouse School of Medicine, Atlanta, GA, is a researcher working on the pivotal PD GENEration study, which aims to improve treatment options through the identification of clinically relevant genes linked to Parkinson disease. In this episodYoung-Onset ALS: Diagnosis and Research
https://practicalneurology.com/diseases-diagnoses/neuromuscular/young-onset-als-diagnosis-and-research/30098/In this episode, Gwen Petersen discusses her long journey to receiving an ALS diagnosis at age 32, her contributions to a Cytokinetics book project, and the importance of clinical trial participation. We are also joined by Merit Cudkowicz, MD, MSc, Head of the Department of Neurology, Chief of NeuroNMOSD Part 2 - The importance and tools for monitoring NMOSD, and signs, symptoms and evaluation of disease activity
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/nmosd-part-2-the-importance-and-tools-for-monitoring-nmosd-and-signs-symptoms-and-evaluation-of-disease-activity/30088/In this series, Derrick Robertson, MD, Director of the Multiple Sclerosis Division at the University of Southern Florida discusses multiple aspects of NMOSD. Dr. Robertson is talking with us today on behalf of Horizon Therapeutics which is compensating him for his services and is sponsoring this podSurviving Stroke: 2 Surgeons Experience with Recovery
https://practicalneurology.com/diseases-diagnoses/stroke/surviving-stroke-2-surgeons-experience-with-recovery/30087/Siva Murugappan, MD, General Surgeon, Chatham-Kent Health Alliance, Ontario, Canada, shares his own experiences as a patient recovering from an ischemic stroke. He is joined by his wife and caregiver, Dr. Prema Samy, Otolaryngologist, Chatham-Kent Health Alliance, Ontario, Canada, as they both discuVagus Nerve Stimulation: Effects Beyond the Nervous System
https://practicalneurology.com/programs/practical-neurology/vagus-nerve-stimulation-effects-beyond-the-nervous-system/30101/Stavros Zanos, MD, PhD, Associate Professor, Institute of Bioelectronic Medicine, Feinstein Institutes for Medical Research, uses neurostimulation as a means to study the nervous system and to treat diseases in which the nervous system is affected or implicated. In this episode, Dr. Zanos gives an oProposed Hospital Standards for Parkinson Disease Care Aim to Avoid Preventable Harm
https://practicalneurology.com/programs/practical-neurology/proposed-hospital-standards-for-parkinson-disease-care-aim-to-avoid-preventable-harm/35438/Preventable harm is a serious concern for patients with Parkinson disease who receive care in the hospital setting, even when admitted for reasons other than their diagnosis. Peter Pronovost, MD, PhD, FCCM, Chief Quality and Transformation Officer at University Hospitals Cleveland Medical Center, ClRedefining Life with Friedreich Ataxia
https://practicalneurology.com/diseases-diagnoses/neuromuscular/redefining-life-with-friedreich-ataxia/30099/We speak with neuromuscular disease expert David Lynch, MD, PhD, attending neurologist in the Division of Neurology at Children's Hospital of Philadelphia and director of the Friedreich Ataxia Program, about the emerging treatment landscape for Friedreich ataxia as well as Kiersten Riggs, who discusNMOSD Part 1 - Overview and important considerations for diagnosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/nmosd-part-1-overview-and-important-considerations-for-diagnosis/30086/In this series, Derrick Robertson, MD, Director of the Multiple Sclerosis Division at the University of Southern Florida discusses multiple aspects of NMOSD. Dr. Robertson is talking with us today on behalf of Horizon Therapeutics which is compensating him for his services and is sponsoring this pod